Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
ResMed: Digital Ecosystem Leadership as the Game Changer—As US Sales Soften, Can Their AI and GLP-1 Tailwinds Redefine the Sleep Health Market?- Evaluating Growth Durability, outlook & its 5 Key Competitive & Strategic Levers !
ResMed’s Q1 FY2025 results showcased robust performance, with revenue rising 11% YoY to $1.22 billion, exceeding expectations by $41.58 million, while adjusted EPS of $2.20 outperformed by $0.16. Growth was driven by strong device sales (+10%) and masks & accessories (+11%) across geographies, supported by innovation like the dual-platform AirSense 10 and 11 strategy and digital health tools such as AirView, myAir, and the AI-powered Dawn system. Gross margins expanded 320 bps to 59.2%, while EBIT grew 27%, reflecting strong operational execution. ResMed’s leadership in patient adherence and digital connectivity, bolstered by GLP-1 tailwinds and consumer wearable-driven awareness, highlights a durable growth runway. Macro tailwinds, such as expanding sleep apnea detection and comorbidity management, align with ResMed’s focus on scaling its ecosystem and advancing adjacent markets like COPD and insomnia. However, near-term challenges include pricing pressures in Europe and Asia, Philips’ re-entry into the market, and geopolitical risks. ResMed’s guidance for 59%-60% gross margins and continued R&D investments underscores confidence in leveraging long-term trends, while its robust liquidity supports growth initiatives and shareholder returns. Can ResMed’s innovation in AI, wearables integration, and GLP-1 leverage redefine the sleep health market and sustain its leadership amidst rising competitive pressures?
